Genetic Influences in Breast Cancer Drug Resistance

Overview

Journal Breast Cancer (Dove Med Press)

Publisher Dove Medical Press

Date 2021 Feb 19

PMID 33603458

Citations 9

Authors

Adhitiya Daniyal

Ivana Santoso

Nadira Hasna Putri Gunawan

Melisa Intan Barliana

Rizky Abdulah

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common cancer in adult women aged 20 to 50 years. The therapeutic regimens that are commonly recommended to treat breast cancer are human epidermal growth factor receptor 2 (HER2) targeted therapy, endocrine therapy, and systemic chemotherapy. The selection of pharmacotherapy is based on the characteristics of the tumor and its hormone receptor status, specifically, the presence of HER2, progesterone receptors, and estrogen receptors. Breast cancer pharmacotherapy often gives different results in various populations, which may cause therapeutic failure. Different types of congenital drug resistance in individuals can cause this. Genetic polymorphism is a factor in the occurrence of congenital drug resistance. This review explores the relationship between genetic polymorphisms and resistance to breast cancer therapy. It considers studies published from 2010 to 2020 concerning the relationship of genetic polymorphisms and breast cancer therapy. Several gene polymorphisms are found to be related to longer overall survival, worse relapse-free survival, higher pathological complete response, and increased disease-free survival in breast cancer patients. The presence of these gene polymorphisms can be considered in the treatment of breast cancer in order to shape personalized therapy to yield better results.

Citing Articles

FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients.

Abdel-Wahed M, Sabbour G, Hamed A, El Kady M, Mohammed S, Shaaban M Sci Rep. 2024; 14(1):26037.

PMID: 39472454 PMC: 11522560. DOI: 10.1038/s41598-024-76024-6.

Novel associations between MTDH gene polymorphisms and invasive ductal breast cancer: a case-control study.

Huang Y, Dai D, Zhu L, Qi X Discov Oncol. 2024; 15(1):273.

PMID: 38977630 PMC: 11231109. DOI: 10.1007/s12672-024-01086-x.

Synthesis, Characterization, and In Vitro Cytotoxicity Evaluation of Doxorubicin-Loaded Magnetite Nanoparticles on Triple-Negative Breast Cancer Cell Lines.

Markhulia J, Kekutia S, Mikelashvili V, Saneblidze L, Tsertsvadze T, Maisuradze N Pharmaceutics. 2023; 15(6).

PMID: 37376206 PMC: 10304410. DOI: 10.3390/pharmaceutics15061758.

Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics.

Subhan M RSC Adv. 2022; 12(51):32956-32978.

PMID: 36425155 PMC: 9670683. DOI: 10.1039/d2ra02005j.

Breast cancer in the era of precision medicine.

Sarhangi N, Hajjari S, Heydari S, Ganjizadeh M, Rouhollah F, Hasanzad M Mol Biol Rep. 2022; 49(10):10023-10037.

PMID: 35733061 DOI: 10.1007/s11033-022-07571-2.

References

Kallel I, Kharrat N, Al-fadhly S, Rebai M, Khabir A, Boudawara T . HER2 polymorphisms and breast cancer in Tunisian women. Genet Test Mol Biomarkers. 2009; 14(1):29-35. DOI: 10.1089/gtmb.2009.0069. View

Xie F, Jin K, Shao L, Fan Y, Tu Y, Li Y . FAF1 phosphorylation by AKT accumulates TGF-β type II receptor and drives breast cancer metastasis. Nat Commun. 2017; 8:15021. PMC: 5414047. DOI: 10.1038/ncomms15021. View

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C . Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006; 94(2):259-67. PMC: 2361112. DOI: 10.1038/sj.bjc.6602930. View

Busch S, Sims A, Stal O, Ferno M, Landberg G . Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance. Cancer Res. 2015; 75(7):1457-69. DOI: 10.1158/0008-5472.CAN-14-1583. View

Regan M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R . CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012; 104(6):441-51. PMC: 3309132. DOI: 10.1093/jnci/djs125. View

Chang H, Rha S, Jeung H, Im C, Ahn J, Kwon W . Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2008; 20(2):272-7. DOI: 10.1093/annonc/mdn624. View

Fleishman S, Schlessinger J, Ben-Tal N . A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A. 2002; 99(25):15937-40. PMC: 138543. DOI: 10.1073/pnas.252640799. View

Dezentje V, van Schaik R, Vletter-Bogaartz J, van der Straaten T, Wessels J, Kranenbarg E . CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Breast Cancer Res Treat. 2013; 140(2):363-73. DOI: 10.1007/s10549-013-2619-6. View

Dhakal H, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E . Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness. Histopathology. 2012; 61(3):350-64. DOI: 10.1111/j.1365-2559.2012.04223.x. View

10.

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

11.

Romero A, Martin M, Oliva B, de la Torre J, Furio V, de la Hoya M . Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol. 2011; 23(7):1750-6. DOI: 10.1093/annonc/mdr483. View

12.

Hwang G, Bhat R, Crutchley R, Trivedi M . Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes. Pharmacogenomics J. 2017; 18(2):201-208. DOI: 10.1038/tpj.2017.36. View

13.

Burstein H, Temin S, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32(21):2255-69. PMC: 4876310. DOI: 10.1200/JCO.2013.54.2258. View

14.

Hou H, Sun D, Zhang X . The role of amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int. 2019; 19:216. PMC: 6704499. DOI: 10.1186/s12935-019-0937-4. View

15.

Hu D, Rogers A, Mackenzie P . Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. Mol Pharmacol. 2014; 85(6):887-97. DOI: 10.1124/mol.114.091603. View

16.

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E . Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v8-30. DOI: 10.1093/annonc/mdv298. View

17.

Geisler S, Lonning P, Aas T, Johnsen H, Fluge O, Haugen D . Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001; 61(6):2505-12. View

18.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

19.

Shibuya M . Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2012; 153(1):13-9. PMC: 3528006. DOI: 10.1093/jb/mvs136. View

20.

Gregory B, Chen S, Murphy M, Atchley D, Kamdem L . Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers. J Clin Pharm Ther. 2017; 42(5):547-553. PMC: 5646416. DOI: 10.1111/jcpt.12569. View